4 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Service d'aide à la décision clinique

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

  • You can purchase this item in Pay Per ViewPay per View - FAQ : 33,00 € Taxes included to order
    Pages Iconography Videos Other
    11 4 0 0

Gynécologie Obstétrique & Fertilité
Volume 33, n° 6
pages 371-381 (juin 2005)
Doi : 10.1016/j.gyobfe.2005.01.005
Received : 18 January 2005 ;  accepted : 1 April 2005
Intérêt de la tomographie par émission de positons au [18F]-fluorodésoxyglucose dans le diagnostic, le bilan d'extension et la recherche de récidive des cancers gynécologiques et mammaires
Role of [18F]-fluorodeoxyglucose positron emission tomography for the initial detection, staging, search for recurrences and restaging of gynaecological and breast cancers

D. Grahek a, , E. Barranger b, E. Daraï b, S. Uzan b, J.-N. Talbot a
a Centre TEP et service de médecine nucléaire, hôpital Tenon, 4, rue de la Chine, 75020 Paris, France 
b Service de gynécologie-obstétrique, hôpital Tenon, 4, rue de la Chine, 75020 Paris, France 

*Auteur correspondant.

La tomographie par émission de positons (TEP) au [18F]-fluorodésoxyglucose (FDG) est une modalité d'imagerie qui devient accessible en France. De nombreux centres en sont ou en seront prochainement équipés. Les indications de la TEP sont bien établies dans certaines pathologies comme le lymphome ou le cancer pulmonaire, ce qui n'est pas encore le cas dans les cancers gynécologiques et mammaires. Nous avons essayé de préciser l'intérêt de la TEP-FDG pour la détection, le bilan d'extension et la recherche de récidive dans les cancers du sein, de l'ovaire, du col utérin et du corps de l'utérus.

The full text of this article is available in PDF format.

Positron emission tomography (PET) using fluorodeoxyglucose (FDG) is a new metabolic imaging modality that is becoming accessible in France. Many centers have been or will be equipped soon. The indications of PET-FDG have been established in various settings in some oncology pathologies such as lymphoma or lung cancer, but not in gynaecological and breast cancers. Therefore, we aimed to precise the interest of PET-FDG to detect, stage and restage the cancers of breast, ovary, cervix and uterus by reviewing the recent publications.

The full text of this article is available in PDF format.

Mots clés : TEP-FDG, Cancer du sein, Cancer de l'ovaire, Cancer du col utérin, Cancer de l'utérus

Keywords : FDG-PET, Breast cancer, Ovarian cancer, Cervical cancer, Uterine cancer

© 2005  Elsevier SAS. All Rights Reserved.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline